Immunosuppressive biological mechanisms support reassessment of use of the injectable contraceptive medroxyprogesterone acetate

Endocrinology

Volumn 154, Issue 3, 2013, Pages 985-988

  Hapgood, Janet P ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ENANTATE; STEROID RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL FUNCTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; GENE FUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; OBSERVATIONAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; T LYMPHOCYTE ACTIVATION; TARGET ORGAN; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAMUSCULAR; MEDROXYPROGESTERONE ACETATE; MODELS, IMMUNOLOGICAL; RISK FACTORS;

EID: 84874604749     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1066     Document Type: Article

References (22)

1. Morrison CS, Skoler-Karpoff S, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS. 2012;26:497-504.
2. Morrison CS, Chen P, Kwok C, et al. Hormonal contraception and HIV acquisition: Reanalysis using marginal structural modeling. AIDS. 2010;24:1778-1781.
3. Morrison CS, Nanda K. Hormonal contraception and HIV: An unanswered question. Lancet Infect Dis. 2012;12:2-3.
4. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: A prospective cohort study. Lancet Infect Dis. 2012;12:19-26.
5. Blish CA, Baeten JM. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol. 2011;65:302-307.
6. Gray RH. Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect Dis. 2012;12:507-508.
7. Kumwenda J, Makanani B, Taulo F, et al. Natural history and the risk factors associated with early and established HIV type 1 infection among reproductive-age women in Malawi. Clin Infect Dis. 2008;46:1913-1920.
8. Jain AK. Hormonal contraception and HIV acquisition risk: Implications for individual users and public policies. Contraception. 2012;86:645-652.
9. World Health Organization. Hormonal Contraception and HIV: Technical Statement. Geneva, Switzerland: World Health Organization; 2012.
10. Huijbregts RP, Helton ES, Michel KG, et al. 2013 Hormonal contraception and HIV-1 infection: Medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology. 2013;154:1282-1295.
11. Hapgood JP, Koubovec D,LouwA, Africander D. Not all progestins are the same: Implications for usage. Trends Pharmacol Sci. 2004; 25:554-557.
12. Koubovec D, Vanden W, Vermeulen L, Haegeman G, Hapgood JP. Medroxyprogesterone acetate downregulates cytokine gene expression in mouse fibroblast cells. Mol Cell Endocrinol. 2004;221:75- 85.
13. Koubovec D, Ronacher K, Stubsrud E, Louw A, Hapgood JP. Synthetic progestins used in HRT have different glucocorticoid agonist properties. Mol Cell Endocrinol. 2005;242:23-32.
14. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011;76:636-652.
15. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy-differences in their pharmacological properties, intracellular actions, and clinical effects [published online ahead of print December 13, 2012]. Endocr Rev. DOI:10.1210/er.2012-1008.
16. Ronacher K, Hadley K, Avenant C, et al. Ligand-selective transactivation and transrepression via the glucocorticoid receptor: Role of cofactor interaction. Mol Cell Endocrinol. 2009;299:219-231.
17. Kleynhans L, Du Plessis N, Black GF, et al. Medroxyprogesterone acetate alters Mycobacterium bovis BCG-induced cytokine production in peripheral blood mononuclear cells of contraceptive users. Plos One. 2011;6:e24639.
18. Hel Z, Stringer E, Mestecky J. Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev. 2010;31:79-97.
19. Miguel RD, Hendricks RL, Aguirre AJ, et al. Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection. J Immunol. 2012;189:3449-3461.
20. Zhao Q, Pang J, Favata M, Trzaskos J. Receptor density dictates the behavior of a subset of steroid ligands in glucocorticoid receptormediated transrepression. Int Immunopharmacol. 2003;3:1803- 1817.
21. Bamberger CM, Else T, Bamberger A, Beil FU, Schulte HM. Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab. 1999;84: 4055-4061.
22. Hapgood JP, Tomasicchio M. Modulation of HIV-1 virulence via the host glucocorticoid receptor: Towards further understanding the molecular mechanisms of HIV-1 pathogenesis. Arch Virol. 2010; 155:1009-1019.